Advertisement

Journal of Endocrinological Investigation

, Volume 36, Issue 2, pp 140–145 | Cite as

Thyroid safety in patients treated with liraglutide

  • M. Gallo
Review Article

Abstract

During the last years, various novel anti-diabetic drugs have considerably enriched the therapeutic armamentarium for subjects with Type 2 diabetes. In the meantime, much interest has recently been focused on the potential cardiovascular and oncological adverse effects of these new therapies. As to glucagon-like peptide 1 (GLP-1) analogs, medullary thyroid tumors were reported to be more common in rodent toxicology studies with liraglutide, although the relevance of this finding in humans has been questioned. Analyses of sequential changes in calcitonin levels in several thousands of subjects did not reveal a relationship between liraglutide therapy and plasma calcitonin. Furthermore, no medullary thyroid cancer has been detected in humans taking liraglutide. Nevertheless, the long-term consequences of sustained GLP-1 receptor activation in the human thyroid remain unknown and deserve further investigation.

Key-words

Liraglutide medullary thyroid cancer safety thyroid cancer Type 2 diabetes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kieffer TJ, Habener JL. The glucagon-like peptides. Endocr Rev 1999, 20: 876–913.PubMedCrossRefGoogle Scholar
  2. 2.
    Drucker DJ. The biology of incretin hormones. Cell Metab 2006, 3: 153–65.PubMedCrossRefGoogle Scholar
  3. 3.
    Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87: 1409–39.PubMedCrossRefGoogle Scholar
  4. 4.
    Novo Nordisk. Liraglutide (injection) for the treatment of patients with type 2 diabetes. NDA 22-341. Briefing document. Endocrine and Metabolic Drug Advisory Committee, 2 April 2009. http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm148659.pdf. Accessed January 4, 2012.
  5. 5.
    Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35: 1364–79.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American College of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes: an algorithm for glycemic control. Endocr Pract 2009, 15: 540–59.PubMedCrossRefGoogle Scholar
  7. 7.
    Ceriello A, Gallo M, Armentano V, Perriello G, Gentile S, De Micheli A; Associazione Medici Diabetologi. Personalizing treatment in type 2 diabetes: a self-monitoring of blood glucose inclusive innovative approach. Diabetes Technol Ther 2012, 14: 373–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Waugh N, Cummins E, Royle P, et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2010, 14: 1–248.Google Scholar
  9. 9.
    Lee WC, Conner C, Hammer M. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US. Curr Med Res Opin 2011, 27: 897–906.PubMedCrossRefGoogle Scholar
  10. 10.
    Shyangdan D, Cummins E, Royle P, Waugh N. Liraglutide for the treatment of type 2 diabetes. Health Technol Assess 2011, 15(Suppl 1): 77–86.PubMedGoogle Scholar
  11. 11.
    Davies MJ, Chubb BD, Smith IC, Valentine WJ. Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus. Diabet Med 2012, 29: 313–20.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    McGill JB. Insights from the Liraglutide Clinical Development Program—the Liraglutide Effect and Action in Diabetes (LEAD) studies. Postgrad Med 2009, 121: 16–25.PubMedCrossRefGoogle Scholar
  13. 13.
    Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009, 160: 909–17.PubMedCrossRefGoogle Scholar
  14. 14.
    Astrup A, Rössner S, Van Gaal L, et al; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009, 374: 1606–16.PubMedCrossRefGoogle Scholar
  15. 15.
    Wadden TA, Hollander P, Klein S, et al. Liraglutide Provides Weight Maintenance and Additional Weight Loss after Low Calorie Diet-Induced Weight Loss in Obese Subjects without Diabetes: The SCALE™ Maintenance Study. Diabetes 2011, 60: 1859–P. American Diabetes Association (ADA) 71st Scientific Sessions, San Diego, CA, 2011 (abstract).CrossRefGoogle Scholar
  16. 16.
    Monami M, Cremasco F, Lamanna C, et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011, 2011: 215764.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010, 151: 1473–86.PubMedCrossRefGoogle Scholar
  18. 18.
    Hoff AO, Catala-Lehnen P, Thomas PM, et al. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 2002, 110: 1849–57.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Wang W, Lewin E, Olgaard K. Role of calcitonin in the rapid minute-to-minute regulation of plasma Ca2+ homeostasis in the rat. Eur J Clin Invest 2002, 32: 674–81.PubMedCrossRefGoogle Scholar
  20. 20.
    Persson P, Grunditz T, Axelson J, Sundler F, Häkanson R. Chole-cystokinins but not gastrin-17 release calcitonin from thyroid C-cells in the rat. Regul Pept 1988, 21: 45–56.PubMedCrossRefGoogle Scholar
  21. 21.
    Vitale G, Ciccarelli A, Caraglia M, et al. Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs pentagastrin. Clin Chem 2002, 48: 1505–10.PubMedGoogle Scholar
  22. 22.
    Kurosawa M, Sato A, Shiraki M, Takahashi Y. Secretion of calcitonin from the thyroid gland increases in aged rats. Arch Gerontol Geriatr 1988, 7: 229–38.PubMedCrossRefGoogle Scholar
  23. 23.
    O’Toole K, Fenoglio-Preiser C, Pushparaj N. Endocrine changes associated with the human aging process: III. Effect of age on the number of calcitonin immunoreactive cells in the thyroid gland. Hum Pathol 1985, 16: 991–1000.PubMedCrossRefGoogle Scholar
  24. 24.
    Hirsch PF, Baruch H. Is calcitonin an important physiological substance? Endocrine 2003, 21: 201–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Raue F, Frank-Raue K. Update multiple endocrine neoplasia type 2. Fam Cancer 2010, 9: 449–57.PubMedCrossRefGoogle Scholar
  26. 26.
    Wolfe HJ, Delellis RA. Familial medullary thyroid carcinoma and C cell hyperplasia. Clin Endocrinol Metab 1981, 10: 351–65.PubMedCrossRefGoogle Scholar
  27. 27.
    LiVolsi VA. C cell hyperplasia/neoplasia. J Clin Endocrinol Metab 1997, 82: 39–41.PubMedCrossRefGoogle Scholar
  28. 28.
    Wu LS, Roman SA, Sosa JA. Medullary thyroid cancer: an update of new guidelines and recent developments. Curr Opin Oncol 2010, 23: 22–7.CrossRefGoogle Scholar
  29. 29.
    Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008, 22: 941–53.PubMedCrossRefGoogle Scholar
  30. 30.
    d’Herbomez M, Caron P, Bauters C, et al; French Group GTE (Groupe des Tumeurs Endocrines). Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J Endocrinol 2007, 157: 749–55.PubMedCrossRefGoogle Scholar
  31. 31.
    Bydureon (exenatide) Product Information. 17/06/2011 Bydureon-EMEA/H/C/002020. Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf. Accessed January 4, 2012.
  32. 32.
    Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012, 153: 1538–47.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Hegedüs L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and Ct concentration in humans: lack of evidence of Ct release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011, 96: 853–60.PubMedCrossRefGoogle Scholar
  34. 34.
    Machens A, Schneyer U, Holzhausen HJ, et al. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005, 90: 2029–34.PubMedCrossRefGoogle Scholar
  35. 35.
    Guyétant S, Rousselet MC, Durigon M, et al. Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study. J Clin Endocrinol Metab 1997, 82: 42–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Sosa JA, Udelsman R. Papillary thyroid cancer. Surg Oncol Clin N Am 2006, 15: 585–601.PubMedCrossRefGoogle Scholar
  37. 37.
    Yeomans ND. Omeprazole: short- and long-term safety. Adverse Drug React Toxicol Rev 1994, 13: 145–56.PubMedGoogle Scholar
  38. 38.
    Thurston V, Williams ED. Experimental induction of C cell tumours in thyroid by increased dietary content of vitamin D3. Acta Endocrinol (Copenh) 1982, 100: 41–5.Google Scholar
  39. 39.
    Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide—the FDA’s review of a new antidiabetic therapy. N Engl J Med 2010, 362: 774–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Important drug warning concerning Victoza®. Subject: potential risks of thyroid C-cell tumours and acute pancreatitis associated with Victoza®. http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM258828.pdf. Accessed January 4, 2012.
  41. 41.
    Gier B, Butler PC, Lai CK, Kirakossian D, Denicola MM, Yeh MW. Glucagon like Peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab 2012, 97: 121–31.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Waser B, Beetschen K, Pellegata NS, Reubi JC. Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuro-endocrinology 2011, 94: 291–301.Google Scholar
  43. 43.
    Diamant M, Van Gaal L, Stranks S, et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010, 375: 2234–43.PubMedCrossRefGoogle Scholar
  44. 44.
    Gallo M, Esposito K, Giugliano D. Diabetes medications and cancer: A way out of uncertainty. Diab Res Clin Pract 2012, 97: 175–7.CrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2013

Authors and Affiliations

  1. 1.Oncological EndocrinologyAO Città della Salute e della Scienza-MolinetteTurinItaly

Personalised recommendations